Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "Vaccines"

711 News Found

Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study
News | January 21, 2022

Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study

An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv


SEC recommends regular market approval for Covishield and Covaxin
News | January 20, 2022

SEC recommends regular market approval for Covishield and Covaxin

However, these won’t be available at the nearest chemist store soon


Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
News | January 18, 2022

Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology

Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines


AstraZeneca studies show its booster effective against all variants
News | January 13, 2022

AstraZeneca studies show its booster effective against all variants

New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


Novel preventive vaccine for Parkinson’s move into human trials
Biotech | January 12, 2022

Novel preventive vaccine for Parkinson’s move into human trials

MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Pfizer and Beam enter research collaboration for In Vivo base editing programme
Biotech | January 11, 2022

Pfizer and Beam enter research collaboration for In Vivo base editing programme

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma